Rapid progression of myelodysplastic syndrome to acute myeloid leukemia on sequential azathioprine, IFN-β and copolymer-1 in a patient with multiple sclerosis

Acta Haematologica

Volumn 116, Issue 3, 2006, Pages 207-210

  Then Bergh, Florian ^a,c   Niklas, Alexander ^a   Strauss, Angelika ^d   Von Ahsen, Nicolas ^b   Niederwieser, Dietger ^a   Schwarz, Johannes ^a   Wagner, Armin ^a   Al Ali, Haifa K ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^d NONE

Author keywords

Azathioprine; Copolymer 1; Hematological disorders; Interferon ; Multiple sclerosis

Indexed keywords

AZATHIOPRINE; BETA1A INTERFERON; CYTARABINE; GLATIRAMER; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MITOXANTRONE; PREDNISONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ANAMNESIS; ANEMIA; ARTICLE; BLOOD TOXICITY; CASE REPORT; CHROMOSOME 5; CHROMOSOME DELETION; CHROMOSOME DELETION 5; DISEASE COURSE; DRUG SUBSTITUTION; FEMALE; GENE DELETION; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOMODULATION; LEUKOPENIA; MULTIPLE SCLEROSIS; MYELODYSPLASTIC SYNDROME; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCYTOPENIA; PHYSICAL EXAMINATION; PRIORITY JOURNAL; THROMBOCYTOPENIA;

ACUTE DISEASE; AZATHIOPRINE; DISEASE PROGRESSION; FATAL OUTCOME; FEMALE; HUMANS; INTERFERON-BETA; LEUKEMIA, MYELOID; MIDDLE AGED; MULTIPLE SCLEROSIS; MYELODYSPLASTIC SYNDROMES; PEPTIDES;

EID: 33749545516     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000094683     Document Type: Article

References (24)

1. Markovic-Plese S, Bielekova B, Kadom N, Leist TP, Martin R, Frank JA, McFarland HF: Longitudinal MRI study: the effects of azathioprine in MS patients refractory to interferon-β1b. Neurology 2003;60:1849-1851.
2. Confavreux C, Saddier P, Grimaud J, Moreau T, Adeleine P, Aimard G: Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study. Neurology 1996;46:1607-1612.
3. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, IARC Press, 2001.
4. Schütz E, von Ahsen N, Oellerich M: Genotyping of eight thiopurine methyltransferase mutations: three-color multiplexing, 'two-color/shared' anchor, and fluorescence-quenching hybridization probe assays based on thermodynamic nearest-neighbor probe design. Clin Chem 2000;46:1728-1737.
5. Au WY, Yuen MF, Lai KC, Wan TS, Ma SK: Clonal marrow abnormalities after azathioprine and sulfasalazine exposure in Crohn's disease: a cautionary tale. Leuk Lymphoma 2002;43:1679-1681.
6. Willerding-Mollmann S, Wilkens L, Schlegelberger B, Kaiser U: Azathioprine-associated myelodysplastic syndrome with cytogenetic aberrations. Dtsch Med Wochenschr 2004;129:1246-1248.
7. Offman J, Opelz G, Doehler B, Cummins D, Halil O, Banner NR, Burke MM, Sullivan D, Macpherson P, Karran P: Defective DNA mismatch repair in acute myeloid leukemia/myelodysplastic syndrome after organ transplantation. Blood 2004;104:822-828.
8. Kwong YL, Au WY, Liang RH: Acute myeloid leukemia after azathioprine treatment for autoimmune diseases: association with -7/7q-. Cancer Genet Cytogenet 1998;104:94-97.
9. Knipp S, Hildebrandt B, Richter J, Haas R, Germing U, Gattermann N: Secondary myelodysplastic syndromes following treatment with azathioprine are associated with aberrations of chromosome 7. Haematologica 2005;90:691-693.
10. Enright H, Miller W: Autoimmune phenomena in patients with myelodysplastic syndromes. Leuk Lymphoma 1997;24:483-489.
11. Ohno T, Hishizawa M, Sugiyama T, Mizumoto T, Furukawa H: The 5q- syndrome associated with marked erythroid hypoplasia and Coombs test positive hemolysis (in Japanese). Rinsho Ketsueki 1999;40:499-504.
12. Giagounidis A, Haase S, Germing U, Heinsch M, Aul C: Autoimmune disorders in two patients with myelodysplastic syndrome and 5q deletion. Acta Haematol 2005;113:146-149.
13. Smith MA, Smith JG: The occurrence subtype and significance of haematopoietic inhibitory T cells (HIT cells) in myelodysplasia: an in vitro study. Leuk Res 1991;15:597-601.
14. Molldrem J J, Leifer E, Bahceci E, Saunthararajah Y, Rivera M, Dunbar C, Liu J, Nakamura R, Young NS, Barrett AJ: Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Ann Intern Med 2002;137:156-163.
15. Mundle SD, Ali A, Cartridge JD, Reza S, Alvi S, Showel MM, Mativi BY, Shetty VT, Venugopal P, Gregory SA, Raza A: Evidence for involvement of tumor necrosis factor-α in apoptotic death of bone marrow cells in myelodysplastic syndromes. Am J Hematol 1999;60:36-47.
16. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-2088.
17. Parmar S, Platanias LC: Interferons: mechanisms of action and clinical applications. Curr Opin Oncol 2003;15:431-439.
18. Tanvetyanon T, Stadtmauer EA, Kerson LA: Concurrent administration of interferon-α2b and β1a. Ann Pharmacother 2003;37:77-79.
19. Fayad L, Kantarjian H, O'Brien S, Seong D, Albitar M, Keating M, Talpaz M: Emergence of new clonal abnormalities following interferon-α induced complete cytogenetic response in patients with chronic myeloid leukemia: report of three cases. Leukemia 1997;11:767-771.
20. Yong VW, Chabot S, Stuve O, Williams G: Interferon-β in the treatment of multiple sclerosis: mechanisms of action. Neurology 1998;51:682-689.
21. Vicari AM, Ciceri F, Folli F, Lanzi R, Colombo B, Comi G, Camba L: Acute promyelocytic leukemia following mitoxantrone as single agent for the treatment of multiple sclerosis. Leukemia 1998;12:441-442.
22. Brassat D, Recher C, Waubant E, Le Page E, Rigal-Huguet F, Laurent G, Edan G, Clanet M: Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS. Neurology 2002;59:954-955.
23. Gold R, Rieckmann P, Chang P, Abdalla J: The long-term safety and tolerability of high-dose interferon-β1a in relapsing-remitting multiple sclerosis: 4-year data from the PRISMS study. Eur J Neurol 2005;12:649-656.
24. Herndon RM, Rudick RA, Munschauer FE 3rd, Mass MK, Salazar AM, Coats ME, Labutta R, Richert JR, Cohan SL, Genain C, Goodkin D, Toal M, Riester K: Eight-year immunogenicity and safety of interferon-β1a-Avonex treatment in patients with multiple sclerosis. Mult Scler 2005;11:409-419.